Skip to main content

Table 3 Expression of biomarkers across different histological subtypes

From: Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases

Subtype (n)

P53 ≥ 10% n (%)

n = 74

tcPD-L1 median, (range)

n = 73

icPD-L1

median, (range)

n = 73

tcPD-L1 ≥ 1% n (%)

n = 73

icPD-L1 ≥ 1%

n (%)

n = 73

γH2AX median,

(range)

n = 75

RPA2 median, (range)

n = 74

iTIL

median, (range) n = 76

sTIL median, (range) n = 76

Low grade adenosquamous (1)

0 (0)

0 (0–0)

30 (30–30)

0 (0)

1 (100)

  

0 (0–0)

5 (5–5)

Squamous (19)

15 (83)

13 (0 – 100)

20 (0 – 60)

11 (61)

13 (72)

43 (8 – 78)

40 (7 – 73)

1 (0 – 10)

7 (0 – 60)

Spindle (17)

12 (71)

30 (0 – 100)

5 (0 – 80)

13 (77)

12 (71)

43 (6 – 85)

40 (3 – 75)

3 (0 – 20)

3 (0 – 40)

Carcinoma with mesenchymal differentiation (13)

8 (62)

0 (0 – 5)

0 (0 – 40)

3 (25)

4 (33)

49 (15 – 83)

58 (12 – 81)

0 (0 – 2)

0 (0 – 40)

Mixed metaplastic (9)

6 (67)

7 (0 – 100)

20 (0 – 60)

7 (78)

7 (78)

49 (12 – 85)

25 (3 – 75)

1 (0 – 5)

5 (1 – 20)

Mixed type (17)

9 (56)

2 (0 – 90)

1 (0 – 70)

9 (56)

8 (50)

38 (5 – 79)

50 (4 – 80)

0 (0 – 2)

5 (0 – 50)

P value

0.375b

0.010a

0.368a

  

0.893a

0.271a

 < 0.0005a

0.096a

  1. tcPD-L1 tumor cell-PD-L1, icPD-L1 immune cell PD-L1, iTIL % intratumoral tumor-infiltrating lymphocytes, sTIL % stromal tumor-infiltrating lymphocytes
  2. aKruskal-Wallis test
  3. bχ2 test